文献速递乳腺乳腺X线MR

基于人工智能计算机辅助诊断的数字乳腺X线摄影预测HER2阳性和三阴性乳腺癌患者新辅助化疗反应:与MRI比较

Digital mammography with AI-based computer-aided diagnosis to predict neoadjuvant chemotherapy response in HER2-positive and triple-negative breast cancer patients: comparison with MRI.
PubMed 文献 · Eur Radiol · 2025-03-25

本研究开发并验证预测模型,评估基于AI-CAD的数字乳腺X线摄影(DM)预测HER2阳性和三阴性乳腺癌新辅助化疗(NAC)后病理完全缓解(pCR)的能力,并与DCE-MRI比较。验证队列中,以NAC后DM的AI-CAD评分≤16为放射学完全缓解标准的DM-AI-CAD模型预测pCR的AUC高于临床病理模型(0.72 vs 0.62;p=0.01),但MRI模型AUC最高(0.83),联合模型次之(0.78)。

要点

  • NAC后DM的AI-CAD评分≤16作为放射学完全缓解标准,其模型预测pCR的AUC为0.72,高于临床病理模型的0.62。
  • MRI模型预测pCR的AUC最高(0.83),联合模型为0.78,DM-AI-CAD模型低于MRI模型。
  • DM-AI-CAD模型可能用于MRI不可用或有禁忌证的乳腺癌患者预测NAC后pCR。

核心结论

  • 利用NAC后DM的AI-CAD评分≤16的模型预测HER2阳性和三阴性乳腺癌pCR的准确性高于临床病理模型,但低于MRI模型。

研究设计与样本

  • 单中心研究,开发队列259例女性(平均年龄53岁±10.5),验证队列119例(平均年龄50.8岁±11.1),均来自2020年9月至2021年8月及2021年12月至2022年7月接受NAC和手术的HER2阳性或三阴性乳腺癌患者。

诊断标准与关键数值

  • 验证队列中,DM-AI-CAD模型以NAC后DM的AI-CAD评分≤16为放射学完全缓解标准,预测pCR的AUC为0.72;临床病理模型AUC为0.62(p=0.01);MRI模型AUC为0.83;联合模型AUC为0.78。

临床应用与阅片要点

  • DM-AI-CAD模型可能用于MRI不可用或有禁忌证的乳腺癌患者预测NAC后pCR;阅片时需注意以NAC后DM的AI-CAD评分≤16作为放射学完全缓解标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate whether digital mammography (DM) with artificial intelligence-based computer-aided diagnosis (AI-CAD) predicts pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) breast cancers and compare performance with dynamic contrast-enhanced (DCE)-MRI.

MATERIALS AND METHODS: In this single-center study, patients who underwent NAC and surgery for HER2-positive or TN cancers between September 2020 and August 2021 were retrospectively selected to develop prediction models for pCR after NAC. From a prospective ASLAN (Avoid axillary Sentinel Lymph node biopsy After Neoadjuvant chemotherapy) trial, HER2-positive and TN cancer patients who underwent NAC and surgery between December 2021 and July 2022 were prospectively selected for model validation. Clinical-pathologic data and DM and MRI scans were obtained before and after NAC. Logistic regression analyses identified factors associated with pCR for model development and four models (clinical-pathologic, MRI, DM-AI-CAD, and combined) were evaluated.

RESULTS: A total of 259 women (mean age, 53 years ± 10.5 [SD]) constituted the development cohort and 119 (50.8 years ± 11.1) the validation cohort. Age, clinical N stage, estrogen receptor, progesterone receptor, and Ki-67 were incorporated into the clinical-pathologic model. In the validation cohort, the DM-AI-CAD model, applying AI-CAD score ≤ 16 on post-NAC DM as the radiologic CR criterion, showed a higher area under the receiver operating characteristic curve (AUC) compared to the clinical-pathologic model (0.72 vs. 0.62; p = 0.01) for pCR. However, the MRI model showed the highest AUC (0.83), then the combined model (0.78).

CONCLUSION: The model utilizing post-NAC DM with AI-CAD score ≤ 16 predicted pCR more accurately than the clinical-pathologic model in HER2-positive and TN cancers but was inferior to the MRI model.

KEY POINTS: Question The performance of digital mammography (DM) with AI-based computer-aided diagnosis (AI-CAD) for predicting pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is unclear. Findings The DM-AI-CAD model incorporating AI-CAD score ≤ 16 on post-NAC DM predicted pCR more accurately than the clinical-pathologic model but not the MRI model. Clinical relevance The DM-AI-CAD model has potential to predict pCR after NAC in breast cancer patients for whom MRI is unavailable or contraindicated.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim H, Choi JS, Chi SA, et al. Digital mammography with AI-based computer-aided diagnosis to predict neoadjuvant chemotherapy response in HER2-positive and triple-negative breast cancer patients: comparison with MRI. Eur Radiol. 2025. PMID: 40131473. doi:10.1007/s00330-025-11390-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。